Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
65°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(OP:
POLBF
)
0.1100
UNCHANGED
Last Price
Updated: 9:30 AM EDT, Apr 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
0.1100
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.1100
Today's Range
0.1100 - 0.1100
52wk Range
0.1070 - 0.1100
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Poolbeg Pharma PLC Announces POLB 001 US Patent Update
March 19, 2024
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Director Share Purchase
February 19, 2024
Via
ACCESSWIRE
Performance
YTD
+2.80%
+2.80%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
+2.80%
+2.80%
1 Year
+2.80%
+2.80%
More News
Read More
Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP
February 14, 2024
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Market Opportunity for POLB 001 for CRS
February 11, 2024
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Further Data Shows POLB001 Potential in Cancer CRS
January 16, 2024
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces RSV AI Drug Candidate Analysis Update
December 19, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 Data Presented at ASH
December 11, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Directorate Change
November 30, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Immunomodulator II Patent Granted in Japan
November 21, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 LPS Trial Data to be Presented at IUIS
November 16, 2023
Via
ACCESSWIRE
Former Amryt Pharma Leadership Team join Poolbeg
November 09, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 Data to be Presented at American Society of Hematology Annual Meeting
November 03, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces POLB 001 Oncology Programme Update Meeting
November 01, 2023
Via
ACCESSWIRE
Poolbeg Pharma unveils new collaboration agreement
October 18, 2023
Via
News Direct
Poolbeg Pharma unveils new collaboration agreement
October 18, 2023
Via
TheNewswire.com
Poolbeg Partners with a Nasdaq-Listed Biopharma
October 17, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition
September 29, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces Immunomodulator I Patent Opposition Withdrawal
September 19, 2023
Via
ACCESSWIRE
Poolbeg Pharma "moving forward rapidly" with POLB001
September 13, 2023
Via
News Direct
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Poolbeg Pharma "moving forward rapidly" with POLB001
September 13, 2023
Via
TheNewswire.com
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Poolbeg Pharma PLC Announces Interim Results for the Six Months to 30 June 2023
September 13, 2023
Via
ACCESSWIRE
Poolbeg Pharma PLC Announces AI Led Programme Identifies Influenza Drug Targets
June 29, 2023
Via
ACCESSWIRE
Poolbeg Pharma and CytoReason identify "very exciting influenza targets"
June 29, 2023
Via
News Direct
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Poolbeg Pharma and CytoReason identify "very exciting influenza targets"
June 29, 2023
Via
TheNewswire.com
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Poolbeg Pharma sees "significant commercial opportunity" in oral vaccines
June 22, 2023
Via
News Direct
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.